<DOC>
	<DOCNO>NCT01598363</DOCNO>
	<brief_summary>The purpose study evaluate potential effect bardoxolone methyl pharmacokinetics digoxin rosuvastatin assess safety concomitant administration bardoxolone methyl digoxin rosuvastatin .</brief_summary>
	<brief_title>An Open-Label Study Effect Bardoxolone Methyl Single Dose Pharmacokinetics Digoxin Rosuvastatin Healthy Volunteers</brief_title>
	<detailed_description>Subjects Cohort 1 receive single dose digoxin ( 0.5 mg ) Study Day 1 , initial dose bardoxolone methyl ( 60 mg ) single dose digoxin ( 0.5 mg ) Study Day 10 , daily dose bardoxolone methyl ( 20 mg ) Study Days 11 14 . Subjects Cohort 2 receive single dose rosuvastatin ( 20 mg ) Study Day 1 , initial dose bardoxolone methyl ( 60 mg ) single dose rosuvastatin ( 20 mg ) Study Day 10 , daily dose bardoxolone methyl ( 20 mg ) Study Days 11 14 . All dos give morning fast condition . Bardoxolone methyl probe substrate ( digoxin , rosuvastatin ) dose time . Confinement begin Study Day -1 ( Study Day first dose day ) end collection 216 hour blood sample schedule study procedure Study Day 19 .</detailed_description>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male female subject 18 45 year , inclusive ; Willing practice method birth control ( male partner childbearing potential female childbearing potential ) screening , take study drug , least 30 day last dose study drug ingest ; Body mass index ( BMI ) 19 31 kg/m2 , inclusive ; Willing able give write informed consent study participation ; Willing able cooperate aspect protocol . Participated another clinical trial investigational drug ( medical device ) within 30 day Study Day 1 , currently participate another trial investigational drug ( medical device ) ; Any condition possibly affect absorption , distribution , metabolism excretion drug may confound analysis conduct study ( example : previous surgery gastrointestinal tract include removal part stomach , bowel , liver , gall bladder , pancreas , venacaval shunt , transjugular intrahepatic portosystemic shunt ) ; Known hypersensitivity component formulation bardoxolone methyl , LANOXIN® , CRESTOR® ; Evidence history concurrent clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose administration ) , hematological , endocrine , immunological , renal , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease judgment investigator could potentially either pose health risk subject study influence study outcome ; Evidence hepatic biliary dysfunction include elevation total bilirubin , direct bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gamma glutamyl transpeptidase ( GGT ) , lactate dehydrogenase ( LDH ) , alkaline phosphatase level great upper limit normal ( ULN ) ; Positive test result human immunodeficiency virus type 1 2 antibody , hepatitis B surface antigen , hepatitis C virus antibody screen ; Any medical dental procedure , matter minor , plan anticipate occur conduct study ; History alcohol abuse dependence within last year ; Any vaccination within 30 day start study throughout study ; Use aspirin , nonsteroidal antiinflammatory agent , acetaminophen within 5 day Study Day 1 ; use aspirin nonsteroidal antiinflammatory agent ( acetaminophen ) allow isolated episode pain discretion investigator ; Use need systemic drug ( ) include vitamin herbal preparation drug use contraception , within 30 day entry study study ; Donation receipt blood blood component within 4 week Study Day 1 , The investigator instruct subject participate study donate blood blood component 4 week completion study ; Any diagnostic intervention procedure require contrast agent within 30 day study participation ; Systolic blood pressure &gt; 140mmHg &lt; 100mmHg diastolic blood pressure &gt; 95 mmHg screening measure 5 minute sit position ; A pulse rate rest sit position &lt; 50 bpm &gt; 100 bpm ; Abnormal screen ECG ( include QTcF interval &gt; 450 m ) interpret investigator clinically significant , clinical evidence WolffParkinsonWhite syndrome , intermittent complete heart block , second degree heart block prolong PR interval ≥ 200 msec 12lead ECG ; Use tobacco nicotinecontaining product ( , cigarettes , cigar , chew tobacco , snuff , etc ) product smoke cessation within 2 week Study Day 1 ; Consumed alcohol xanthinecontaining product ( e.g. , tea , coffee , chocolate , cola , etc . ) within 72 hour Study Day 1 ; Treated investigational agent within 30 day Study Day 1 , 5 halflives twice duration biological effect previous investigational drug ( whichever longer ) ; A history drug abuse test positive drug ( ) abuse ( ethanol , amphetamine , benzodiazepine , barbiturate , cocaine , opiates , cannabinoids ) cotinine ( indicate active current smoking ) screening Study Day 1 ; Female subject plan pregnancy pregnant lactating ; Deemed investigator inappropriate study , include subject unable communicate investigator due language problem , poor mental development , impaired cerebral function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>